Despite the importance of the recently enacted federal healthcare law, a remarkable 50% of the public does not know its current status.
June 2011
4 Questions for Martine Piccart-Gebhart, MD, PhD: Noted Breast Cancer Researcher Has Bright Hopes for HER2 Targets
ByOncLive
Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.
The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.
FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.
Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.
During the past 20 years, disease management systems have mushroomed in medicine
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
3
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
4
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
5